The Future of Smallpox Vaccination: is MVA the key?
Eradication of the smallpox virus through extensive global vaccination efforts has resulted in one of the most important breakthroughs in medical history, saving countless lives from the severe morbidity and mortality that is associated with this disease. Although smallpox is now extinct in nature, laboratory stocks of this virus still remain and the subject of smallpox vaccination has gained renewed attention due to the potential risk that smallpox may be used as a biological weapon by terrorists or rogue states. Despite having the longest history of any modern vaccine, there is still much to be learned about smallpox vaccination and the correlates of protection remain to be formally defined. This Commentary will discuss the strengths and weaknesses of traditional smallpox vaccination in comparison with immunization using modified vaccinia virus Ankura (MVA), a non-replicating virus with a strong safety record but weakened immunogenicity.
Slifka
Mark K
MK
Vaccine and Gene Therapy Institute, Oregon Health & Sciences University, 505 NW 185th Avenue, Beaverton, OR 97006, USA. slifkam@ohsu.edu.
Nat Med. 2003 Sep;9(9):1131-7
12925846
J Immunol. 2003 Nov 15;171(10):4969-73
14607890
Lancet. 2005 Jan 29-Feb 4;365(9457):398-409
15680454
JAMA. 1970 Apr 20;212(3):441-4
4392370
N Engl J Med. 1969 Nov 27;281(22):1201-8
4186802
J Virol. 2002 Apr;76(7):3329-37
11884558
Nat Med. 2003 Sep;9(9):1125-30
12925845
Vaccine. 2000 Oct 15;19(4-5):483-91
11027812
J Exp Med. 2003 Apr 7;197(7):927-32
12668642
Munch Med Wochenschr. 1971 Aug 27;113(35):1149-53
5109577
N Engl J Med. 2002 Apr 25;346(17):1275-80
11923489
Bull World Health Organ. 1973 May;48(5):523-7
4359679
J Immunol. 2004 May 15;172(10):6265-71
15128815
Am J Epidemiol. 2004 Oct 1;160(7):642-51
15383408
Curr Opin Biotechnol. 2004 Dec;15(6):506-12
15560976
J Infect Dis. 1997 Apr;175(4):756-63
9086127
Nature. 2004 Mar 11;428(6979):182-5
15014500
J Gen Virol. 1998 Feb;79 ( Pt 2):347-52
9472619
J Virol. 2001 Feb;75(3):1205-10
11152493
Dermatol Clin. 2004 Jul;22(3):263-74, vi
15207308
Am J Trop Med Hyg. 1972 Mar;21(2):214-8
5061278
N Engl J Med. 1967 Jan 19;276(3):125-32
4381041
Emerg Infect Dis. 2001 May-Jun;7(3):434-8
11384521
J Infect Dis. 2002 Jun 1;185(11):1657-9
12023773
Dtsch Med Wochenschr. 1974 Nov 22;99(47):2386-92
4426258
Vaccine. 1995 Apr;13(5):487-93
7639016
N Engl J Med. 2003 Jan 30;348(5):460-3
12496354
Curr Drug Targets Infect Disord. 2003 Sep;3(3):263-71
14529359
Bull World Health Organ. 1975;52(3):307-11
1084801
J Virol. 2004 Apr;78(8):3811-6
15047796
Br J Dermatol. 1994 Nov;131(5):598-607
7999588
Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4590-5
15070762
Trends Microbiol. 1996 Oct;4(10):394-400
8899965
Emerg Infect Dis. 2003 Nov;9(11):1468-70
14718095
Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):217-22
12518065
Nat Rev Immunol. 2002 Jul;2(7):521-7
12094226
Rev Med Virol. 2002 Jul-Aug;12(4):201-9
12125012
Am J Epidemiol. 1971 Sep;94(3):252-68
4999240
N Engl J Med. 2004 Jan 22;350(4):342-50
14736926
JAMA. 2003 Jun 25;289(24):3295-9
12824212
Emerg Infect Dis. 2003 Nov;9(11):1458-61
14718092
Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9458-63
12869693
Curr Opin Immunol. 2004 Aug;16(4):443-50
15245737
MMWR Morb Mortal Wkly Rep. 2003 Oct 3;52(39):933-6
14523370
J Am Coll Cardiol. 2004 Jul 7;44(1):201-5
15234435
Appl Microbiol. 1973 Apr;25(4):539-44
4633476